[go: up one dir, main page]

CY1113224T1 - Νεο αντισωμα αντι-ρlgf - Google Patents

Νεο αντισωμα αντι-ρlgf

Info

Publication number
CY1113224T1
CY1113224T1 CY20121100535T CY121100535T CY1113224T1 CY 1113224 T1 CY1113224 T1 CY 1113224T1 CY 20121100535 T CY20121100535 T CY 20121100535T CY 121100535 T CY121100535 T CY 121100535T CY 1113224 T1 CY1113224 T1 CY 1113224T1
Authority
CY
Cyprus
Prior art keywords
pllgf
antibody
new anti
fragments
pigf
Prior art date
Application number
CY20121100535T
Other languages
English (en)
Inventor
Jean-Marie Stassen
Peter Carmeliet
Désiré Collen
Original Assignee
Thrombogenics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrombogenics N.V. filed Critical Thrombogenics N.V.
Publication of CY1113224T1 publication Critical patent/CY1113224T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει νέα μονοκλωνικά αντισώματα που στοχεύουν στον ΡΙGF και σε θραύσματα και παράγωγα αυτών, πιο συγκεκριμένα σε ανθρωποποιημένα αντισώματα και θραύσματα αυτών για χρήση στη θεραπεία και / ή στην πρόληψη της παθολογικής αγγειογένεσης.
CY20121100535T 2005-03-24 2012-06-12 Νεο αντισωμα αντι-ρlgf CY1113224T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66476805P 2005-03-24 2005-03-24
EP06721544A EP1869085B1 (en) 2005-03-24 2006-03-24 Novel anti-plgf antibody

Publications (1)

Publication Number Publication Date
CY1113224T1 true CY1113224T1 (el) 2016-04-13

Family

ID=36928446

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100535T CY1113224T1 (el) 2005-03-24 2012-06-12 Νεο αντισωμα αντι-ρlgf

Country Status (26)

Country Link
US (3) US7875704B2 (el)
EP (2) EP2447281B1 (el)
JP (2) JP5164829B2 (el)
KR (1) KR101314014B1 (el)
CN (1) CN101184776B (el)
AT (1) ATE549358T1 (el)
AU (2) AU2006227571B8 (el)
BR (1) BRPI0609151B8 (el)
CA (1) CA2601267C (el)
CY (1) CY1113224T1 (el)
DK (1) DK1869085T3 (el)
EA (1) EA013970B1 (el)
ES (2) ES2384110T3 (el)
HR (1) HRP20120477T1 (el)
IL (1) IL185754A (el)
ME (1) ME01446B (el)
MX (1) MX2007011735A (el)
NO (1) NO341877B1 (el)
NZ (1) NZ561763A (el)
PL (1) PL1869085T3 (el)
PT (1) PT1869085E (el)
RS (1) RS52372B (el)
SI (1) SI1869085T1 (el)
UA (1) UA94707C2 (el)
WO (1) WO2006099698A2 (el)
ZA (1) ZA200707258B (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321069T1 (de) * 2000-05-12 2006-04-15 Vlaams Interuniv Inst Biotech Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
BRPI0609151B8 (pt) 2005-03-24 2021-05-25 Life Sciences Res Partners Vzw molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
MX2010011955A (es) * 2008-04-29 2011-01-21 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
SG191639A1 (en) 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2011104348A (ru) 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
MX2011003428A (es) 2008-10-02 2011-07-29 Vib Vzw Inhibicion del factor de crecimiento placentario (plgf) para tratar la leucemia con cromosoma filadelfia positivo.
EP2382472B1 (en) * 2008-12-23 2015-05-06 F.Hoffmann-La Roche Ag Methods and compositions for diagnostic use in cancer patients
WO2010127294A2 (en) * 2009-05-01 2010-11-04 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AR078254A1 (es) 2009-09-01 2011-10-26 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2488658A4 (en) 2009-10-15 2013-06-19 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2648264T3 (es) 2010-03-10 2017-12-29 F. Hoffmann-La Roche Ag Procedimiento para la purificación de soluciones de inmunoglobulinas
CA2804348A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
BR112013004581A2 (pt) 2010-08-26 2017-06-27 Abbvie Inc imunoglobulinas de domínio variável dual e seus usos
PL2785739T3 (pl) 2011-12-01 2017-10-31 Thrombogenics Nv Poprawa wyniku trabekulektomii
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
MY194330A (en) 2012-11-01 2022-11-28 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
EP4154907A1 (en) 2012-12-18 2023-03-29 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
BR112015023797A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN104930353B (zh) * 2015-07-10 2017-08-15 浙江大学 一种城市供水管网的调压减漏评估系统
EP3426685A1 (en) * 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS HEMAGGLUTININS AND USES THEREOF
CA3029074A1 (en) 2016-06-22 2018-01-25 William Warren HARLESS Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN109134650A (zh) * 2018-09-10 2019-01-04 宁波奥丞生物科技有限公司 抗人plgf单克隆抗体的制备方法
EP3976650A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cancer treatment by targeting plexins in the immune compartment
EP3976067A1 (en) 2019-05-28 2022-04-06 Vib Vzw Cd8+ t-cells lacking plexins and their application in cancer treatment
WO2020260595A1 (en) 2019-06-26 2020-12-30 Oncurious Nv Combination treatment of medulloblastoma using a placental growth factor inhibitor and a chemotherapeutic agent
EP3936868A1 (en) 2020-07-10 2022-01-12 Charité - Universitätsmedizin Berlin A ratio between plgf and sflt1 is predictive for neural invasion in patients suffering from pancreatic cancer
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
WO2022099465A1 (zh) * 2020-11-10 2022-05-19 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其制备方法和应用
CN112358546B (zh) * 2020-11-10 2022-04-01 宁波奥丞生物科技有限公司 杂交瘤细胞株9c1、plgf-1单克隆抗体及其应用
JP2023554520A (ja) 2020-12-22 2023-12-27 コビオレス エヌヴイ テトラペプチド部分を含む化合物
CN113999310A (zh) * 2020-12-30 2022-02-01 江苏普若维生物技术有限责任公司 一种plgf单克隆抗体、试剂盒、其制备方法和应用
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety
CA3211257A1 (en) 2021-02-17 2022-08-25 Vib Vzw Inhibition of slc4a4 in the treatment of cancer
WO2023118294A1 (en) 2021-12-22 2023-06-29 Vib Vzw Inhibition of mitoferrin 2 as means for inhibiting cancer and cancer metastasis
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2024231348A1 (en) 2023-05-11 2024-11-14 Vib Vzw Slc4a4/nbce1 inhibitors
WO2024260720A1 (en) 2023-06-20 2024-12-26 Vib Vzw Use of intra-tumoral cd8 temra cells for predicting response of a cancer patient to checkpoint inhibitor therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5770198A (en) 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
CA2132091C (en) 1992-04-03 2008-09-16 Kyung J. Kim Antibodies to alphavbeta3 integrin
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
CN1209068A (zh) 1995-10-23 1999-02-24 海欧制药澳大利亚有限公司 作为基因治疗所用的dna载体的透明质酸及治疗异常视网膜血管化的vegf反义dna
DE69736860T2 (de) 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
EP1064382B1 (en) 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
JPH11302193A (ja) * 1998-04-22 1999-11-02 Toagosei Co Ltd 血管新生阻害剤
CA2332336A1 (en) 1998-05-26 1999-12-02 Erik Depla Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
JP2001086982A (ja) 1999-07-16 2001-04-03 Shunpei Niida 骨吸収調節薬
JP2003528824A (ja) 2000-02-04 2003-09-30 スプラテック ファーマ インコーポレイティド 血管内皮成長因子受容体のためのリガンド
ATE321069T1 (de) 2000-05-12 2006-04-15 Vlaams Interuniv Inst Biotech Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
CN1511040A (zh) * 2001-05-25 2004-07-07 ����˹���ѷ��ѧ 作为多种治疗模式基础的蛋白质的选择性剪接形式
US7139817B1 (en) * 2001-06-12 2006-11-21 Network Appliance, Inc. Managing configuration information for multiple devices
AU2002316305A1 (en) 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases
EP1482975B1 (en) 2002-01-29 2006-12-13 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Prevention of tissue adhesion
JP5111729B2 (ja) 2002-06-05 2013-01-09 ジェネンテック， インコーポレイテッド 肝成長及び肝保護のための組成物と方法
JP2005535634A (ja) 2002-06-28 2005-11-24 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） Ｆｌｔ−１に対する抗体の骨粗鬆症の処置のための使用
CA2448769A1 (en) * 2002-11-08 2004-05-08 Primagen Holding B.V. Method for quantifying a ratio between at least two nucleic acid sequences
JP2006519842A (ja) * 2003-03-10 2006-08-31 カリスト・ファーマシューティカルズ・インコーポレイテッド アザスピラン化合物による癌治療法
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
BRPI0609151B8 (pt) 2005-03-24 2021-05-25 Life Sciences Res Partners Vzw molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
MX2011003428A (es) 2008-10-02 2011-07-29 Vib Vzw Inhibicion del factor de crecimiento placentario (plgf) para tratar la leucemia con cromosoma filadelfia positivo.

Also Published As

Publication number Publication date
US9085617B2 (en) 2015-07-21
US20110123525A1 (en) 2011-05-26
US8758748B2 (en) 2014-06-24
KR20080016794A (ko) 2008-02-22
AU2011201340B2 (en) 2012-02-23
HRP20120477T1 (hr) 2012-07-31
JP2008532557A (ja) 2008-08-21
EA200702064A1 (ru) 2008-02-28
BRPI0609151A2 (pt) 2010-02-17
DK1869085T3 (da) 2012-06-18
PL1869085T3 (pl) 2012-09-28
AU2011201340A1 (en) 2011-04-14
EP2447281A1 (en) 2012-05-02
US7875704B2 (en) 2011-01-25
ZA200707258B (en) 2008-06-25
HK1116803A1 (en) 2009-01-02
EP1869085A2 (en) 2007-12-26
NZ561763A (en) 2009-02-28
AU2006227571B8 (en) 2011-01-27
WO2006099698A3 (en) 2006-11-30
EP1869085B1 (en) 2012-03-14
PT1869085E (pt) 2012-06-01
UA94707C2 (en) 2011-06-10
WO2006099698A2 (en) 2006-09-28
SI1869085T1 (sl) 2012-07-31
CA2601267C (en) 2014-02-18
ME01446B (me) 2013-12-20
CN101184776A (zh) 2008-05-21
IL185754A0 (en) 2008-01-06
CN101184776B (zh) 2013-04-24
AU2006227571B2 (en) 2010-12-23
NO341877B1 (no) 2018-02-12
IL185754A (en) 2013-02-28
JP2012136522A (ja) 2012-07-19
ATE549358T1 (de) 2012-03-15
CA2601267A1 (en) 2006-09-28
EA013970B1 (ru) 2010-08-30
ES2565481T3 (es) 2016-04-05
AU2006227571A1 (en) 2006-09-28
JP5164829B2 (ja) 2013-03-21
BRPI0609151B8 (pt) 2021-05-25
US20080193455A1 (en) 2008-08-14
NO20074563L (no) 2007-12-18
EP2447281B1 (en) 2015-12-16
KR101314014B1 (ko) 2013-10-02
RS52372B (en) 2012-12-31
ES2384110T3 (es) 2012-06-29
US20140178397A1 (en) 2014-06-26
BRPI0609151B1 (pt) 2020-01-21
MX2007011735A (es) 2008-03-14

Similar Documents

Publication Publication Date Title
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
NL301089I2 (nl) imlifidase
HUE048404T2 (hu) Claudin-18 elleni monoklonális antitestek rák kezelésére
DE602006013029D1 (de) Anti-egfr-antikörper
UA92504C2 (en) Anti-myostatin monoclonal antibody
CY1120365T1 (el) Αντισωματα εναντι της il-17
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
WO2005003169A3 (en) Modified antibody fab fragments
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
EA200901500A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ATE545657T1 (de) Tgf-beta antikörper
EA200802168A1 (ru) Гуманизированное антитело к с-kit
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
WO2007033140A3 (en) Prok2 antagonists and methods of use
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
DK1771732T3 (da) Taxol-immunassay
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
CY1115979T1 (el) Αντισωματα κατα της μυοστατινης
HK1154251A1 (zh) 抗人類α-干擾素的人類化抗體
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2